Organogenesis (NASDAQ:ORGO) Stock Price Up 6.2%
Organogenesis Holdings Inc (NASDAQ:ORGO)’s share price rose 6.2% during mid-day trading on Friday . The company traded as high as $5.24 and last traded at $5.11, approximately 505,352 shares were traded during mid-day trading. An increase of 394% from the average daily volume of 102,388 shares. The stock had previously closed at $4.81.
Several equities analysts recently commented on the stock. Zacks Investment Research raised shares of Organogenesis from a “hold” rating to a “buy” rating and set a $8.75 target price on the stock in a report on Saturday, November 16th. Credit Suisse Group assumed coverage on shares of Organogenesis in a research note on Monday, August 26th. They issued an “outperform” rating for the company. Six equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $10.46.
The firm has a fifty day moving average of $6.67 and a two-hundred day moving average of $6.31. The company has a current ratio of 1.43, a quick ratio of 1.07 and a debt-to-equity ratio of 7.65.
In other news, Director Avista Capital Managing Member bought 6,000,000 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were purchased at an average price of $5.00 per share, for a total transaction of $30,000,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders have bought 7,401,503 shares of company stock valued at $37,960,069. Insiders own 70.40% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of ORGO. BlackRock Inc. boosted its position in Organogenesis by 716.3% during the 2nd quarter. BlackRock Inc. now owns 554,838 shares of the company’s stock valued at $4,217,000 after buying an additional 486,870 shares during the period. Vanguard Group Inc. increased its position in shares of Organogenesis by 33.3% in the second quarter. Vanguard Group Inc. now owns 323,292 shares of the company’s stock valued at $2,457,000 after acquiring an additional 80,852 shares during the period. State Street Corp increased its position in shares of Organogenesis by 2.3% in the third quarter. State Street Corp now owns 125,843 shares of the company’s stock valued at $827,000 after acquiring an additional 2,837 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Organogenesis by 36.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 86,495 shares of the company’s stock valued at $658,000 after acquiring an additional 23,180 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Organogenesis by 134.3% during the second quarter. Northern Trust Corp now owns 41,066 shares of the company’s stock valued at $312,000 after acquiring an additional 23,540 shares during the last quarter. 2.00% of the stock is currently owned by institutional investors.
Organogenesis Company Profile (NASDAQ:ORGO)
Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.
Featured Story: What is the significance of a dead cat bounce?
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.